This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into Gilead's Trodelvy (sacituzimab govitecan-hziy) after FDA approval in pre-treated HR+/HER2- metastatic breast cancer

Ticker(s): GILD

Who's the expert?

Institution: StonyBrook Cancer Center

  • Chief, Division of Hematology/Oncology and Associate Director of Clinical and Translational Research at Stony Brook Cancer Center.
  • Manages approximately 10 patients with HR+/HER2- mBC.
  • Clinical research in breast cancer include biomarker discovery including the use of functional imaging for predicting breast cancer risk and response to antitumor therapies and role of non-steroidal anti-inflammatory drugs (NSAIDs) in breast cancer prevention.

Interview Questions
Q1.

Roughly how many patients do you manage with HR+/HER2- mBC

Added By: dami_admin
Q2.

On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for trodelvy ?

Added By: dami_admin
Q3.

Please describe your practice as a clinician,how many patients with   HR+/HER2- Metastatic Breast Cancer do you see on a yearly basis? Can you describe the standard of care, and take us through the most promising upcoming treatments?

Added By: dami_admin
Q4.

How much of an unmet need is there for HR+/HER2- Metastatic Breast Cancer? How competitive and effective is Endocrine therapy or Chemotherapy?

Added By: dami_admin
Q5.

Could you walk us through the details regarding Trodelvy’s mechanism of action and composition, and how that translate into beneficial patient outcomes:- Monoclonal antibody: The humanized monoclonal antibody, hRS7 IgG1κ, that binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers, including triple-negative breast cancer (TNBC)- Cytotoxic drug: The camptothecin-derived agent, SN-38, a topoisomerase I inhibitor act by interfering with the replicative capacity of cancer cells.-Linker: A hydrolyzable linker, with a short PEGylated unit.

Added By: dami_admin
Q6.

How do Trodelvy, Trastuzumab emtansine (Kadcyla) and Trastuzumab deruxtecan (Enhertu) compare to eachother?

Added By: dami_admin
Q7.

How likely would you be to use Trodelvy, judging by the clinical trial results to date?

Added By: dami_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.